RT3

Retatrutide (LY3437943) is a synthetic peptide investigated as a molecular research tool for studying three receptor systems: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.

Its triple-receptor agonist profile allows researchers to examine interactions among these signaling pathways within controlled experimental models.

This material is supplied exclusively for laboratory research and analytical applications.

Specifications

Product Classification: Research Use Only (RUO)
Compound: Retatrutide (LY3437943)
Available Content: 10 mg or 30 mg per vial
Classification: GIP / GLP-1 / Glucagon receptor agonist
Form: Lyophilized research material
Packaging: Research vial
Purity: ≥99% (include only when confirmed by the applicable batch COA)
Intended Use: Laboratory research and analytical purposes only

Research Applications

Retatrutide may be used in controlled laboratory models investigating:

• GIP receptor signaling
• GLP-1 receptor signaling
• Glucagon receptor signaling
• Triple-receptor agonism
• Receptor-binding activity
• Intracellular signaling
• Multi-receptor pathway interactions
• Metabolic signaling models

Warning

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE. NOT FOR HUMAN CONSUMPTION.

This product is intended solely for qualified laboratory research and analytical applications.

Scientific Report

Abstract

Retatrutide is a synthetic peptide characterized experimentally by agonist activity across GIP, GLP-1, and glucagon receptors. This triple-receptor profile provides a molecular model for examining the simultaneous activation and interaction of three distinct receptor pathways.

Mechanistic Pathways

GIP Receptor

Retatrutide exhibits agonist activity at the GIP receptor.

Research focus: Receptor activation and downstream GIP-associated signaling.

GLP-1 Receptor

GLP-1 receptor activity represents a second component of the compound's experimental pharmacological profile.

Research focus: GLP-1 receptor activation and associated intracellular signaling.

Glucagon Receptor

Retatrutide also interacts with the glucagon receptor.

Research focus: Glucagon-receptor activation and downstream pathway analysis.

Triple-Receptor Interaction

The defining characteristic of retatrutide as a research compound is the ability to examine three receptor systems using a single molecular platform.

Research focus: Interactions among GIP, GLP-1, and glucagon receptor pathways.

Research Profile

Compound: Retatrutide / LY3437943
Classification: Triple-receptor agonist
Primary Research Areas: GIP, GLP-1, and glucagon receptor signaling
Research Setting: Controlled laboratory and preclinical models

Research Parameters

Experimental concentrations, assay conditions, exposure periods, controls, and endpoints should be selected according to the laboratory model and validated research protocol being used.

No instructions for human or veterinary use are provided.

Research Highlights

• GIP receptor activity
• GLP-1 receptor activity
• Glucagon receptor activity
• Triple-receptor signaling
• Receptor interaction studies
• Intracellular pathway research
• Metabolic signaling models

Conclusion

Retatrutide provides researchers with a molecular tool for studying simultaneous GIP, GLP-1, and glucagon receptor activity and interactions among these pathways under controlled experimental conditions.